Increasing the throughput of commercialized in-licensed assets can have a multi-billion-dollar impact on valuations and create significant funding pools for further pipeline and business development initiatives.
EVERSANA’s in-licensing capabilities were designed to eliminate the capacity and capability constraints faced by large pharmaceutical manufacturers.
By leveraging the robust and bespoke capabilities offered by EVERSANA, there is a substantial opportunity to realize significant growth by drawing more commercial value from increased in-licensing activity.